Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib

Mads Emil Bjørn, Hans Carl Hasselbalch

12 Citationer (Scopus)

Fingeraftryk

Dyk ned i forskningsemnerne om 'Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib'. Sammen danner de et unikt fingeraftryk.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science